Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press6010.17650/2313-805X.2016.3.2.34-41RESEARCH ARTICLESЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИThe study of new anticancer drug delivery system based on the boron nitride nanoparticlesИзучение новых систем доставки противоопухолевых препаратов на основе наночастиц нитрида бораZhitnyakI. Yu.ЖитнякИ. Ю.
Russian Federation
SukhorukovaI. V.СухоруковаИ. В.
Russian Federation
Koval’skiyA. M.КовальскийА. М.
Russian Federation
MatveevA. T.МатвеевА. Т.
Russian Federation
BychkovI. N.БычковИ. Н.
Russian Federation
ShtanskiyD. V.ШтанскийД. В.
Russian Federation
GlushankovaN. A.ГлушанковаН. А.
Russian Federation
natglu@hotmail.comResearch Institute of Carcinogenesis, N.N. Blokhin Russian Cancer Research Center, Ministry of Health of RussiaНИИ канцерогенеза ФГБУ «РОНЦ им. Н. Н. Блохина» Минздрава России24 Kashirskoe Shosse, Moscow, 115478, RussiaРоссия, 115478, Москва, Каширское шоссе, 24National University of Science and Technology, Moscow Institute of Steel and AlloysНациональный исследовательский технологический университет «Московский институт стали и сплавов»4 Leninskiy prospekt, Moscow, 119049, RussiaРоссия, 119991, Москва, Ленинский проспект, 4N.I. Pirogov Russion National Research Medical UniversityГБОУ ВПО «Российский национальный исследовательский университет им. Н.Н. Пирогова»1 Ostrovityanova St., Moscow, 117997, RussiaРоссия, 117997, Москва, ул. Островитянова, 1150520163234410706201607062016Copyright ©; 2016, Zhitnyak I.Y., Sukhorukova I.V., Koval’skiy A.M., Matveev A.T., Bychkov I.N., Shtanskiy D.V., Glushankova N.A.Copyright ©; 2016, Житняк И.Ю., Сухорукова И.В., Ковальский А.М., Матвеев А.Т., Бычков И.Н., Штанский Д.В., Глушанкова Н.А.2016Zhitnyak I.Y., Sukhorukova I.V., Koval’skiy A.M., Matveev A.T., Bychkov I.N., Shtanskiy D.V., Glushankova N.A.Житняк И.Ю., Сухорукова И.В., Ковальский А.М., Матвеев А.Т., Бычков И.Н., Штанский Д.В., Глушанкова Н.А.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/60

The main problem in the treatment of many cancers is multidrug resistance due to tumor progression. Using nanosized drug delivery systems allows to overcome the mechanisms of multidrug resistance of cancer, in this case, chemotherapeutic agents can effectively introduce into cancer cells by endocytosis and accumulate near the nucleus and far from ATP-binding cassette transporters. Creation of boron nitridebased drug delivery nanocarriers with high chemical and oxidative stability is one of the perspective ways. Using chemical vapor deposition spherical boron nitride particles,100–150 nm in diameter (BNNPs), with peculiar petal-like surfaces or smooth surfaces were fabricated. BNNPs were loaded with doxorubicin. Drug loading efficacy of BNNPs-DOX was about 0.095 mg/mg of particles. BNNPs-DOX were relatively stable at neutral pH, whereas DOX is effectively released from the BNNPs at acidic pH (pH 4.5–5.5). Using confocal microscopy, the uptake of BNNPs-DOX by IAR-6-1, KB-3-1, К562 cells and multidrug resistant КВ-8-5 и IS-9 cells was studied. Most of BNNPs-DOX had been co-localized with LysoTracker, indicating that BNNPs-DOX are located in the endosomes/lysosomes after intracellular delivery.

boron nitride nanoparticlesboron nitride nanocarriers loaded with doxorubicinconfocal microscopyendosome/lysosomeнаночастицы нитрида борананоконъюгаты частиц нитрида бора с доксорубициномконфокальная микроскопияэндосома/лизосома1. Kirtane A. R., Kalscheuer S. M., Panyama J. Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev 2013;65(13–14): 1731–47.Kirtane A. R., Kalscheuer S. M., Panyama J. Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev 2013;65(13–14): 1731–47.2. Amin M. L. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 2013;7:27–34.Amin M. L. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 2013;7:27–34.3. Hillaireau H., Couvreur P. Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009;66(17):2873–96.Hillaireau H., Couvreur P. Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009;66(17):2873–96.4. Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev 2013;65(1):21–3.Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev 2013;65(1):21–3.5. Torchilin V. P., Lukyanov A. N. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today 2003;8(6):259–66.Torchilin V. P., Lukyanov A. N. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today 2003;8(6):259–66.6. Oerlemans C., Bult W., Bos M. et al. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 2010;27(12):2569–89.Oerlemans C., Bult W., Bos M. et al. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 2010;27(12):2569–89.7. Kaasgaard T., Andresen T. L. Liposomal cancer therapy: exploiting tumor characteristics. expert opin drug deliv 2010;7(2):225–43.Kaasgaard T., Andresen T. L. Liposomal cancer therapy: exploiting tumor characteristics. expert opin drug deliv 2010;7(2):225–43.8. Mintzer M. A., Grinstaff M. W. Biomedical applications of dendrimers: a tutorial. Chem Soc Rev 2011;40(1):173–90.Mintzer M. A., Grinstaff M. W. Biomedical applications of dendrimers: a tutorial. Chem Soc Rev 2011;40(1):173–90.9. Dreaden E. C., Mackey M. A., Huang X. et al. Beating cancer in multiple ways using nanogold. Chem Soc Rev 2011;40(7): 3391–404.Dreaden E. C., Mackey M. A., Huang X. et al. Beating cancer in multiple ways using nanogold. Chem Soc Rev 2011;40(7): 3391–404.10. Lal S., Clare S. E., Halas N. J. Nanoshellenabled photothermal cancer therapy: impending clinical impact. Acc Chem Res 2008;41(12):1842–51.Lal S., Clare S. E., Halas N. J. Nanoshellenabled photothermal cancer therapy: impending clinical impact. Acc Chem Res 2008;41(12):1842–51.11. Jokerst J. V., Gambhir S. S. Molecular imaging with theranostic nanoparticles. Acc Chem Res 2011;44(10):1050–60.Jokerst J. V., Gambhir S. S. Molecular imaging with theranostic nanoparticles. Acc Chem Res 2011;44(10):1050–60.12. Trewyn B. G., Slowing I. I., Giri S. et al. Synthesis and functionalization of a mesoporous silica nanoparticle based on the sol-gel process and applications in controlled release. Acc Chem Res 2007;40(9):846–53.Trewyn B. G., Slowing I. I., Giri S. et al. Synthesis and functionalization of a mesoporous silica nanoparticle based on the sol-gel process and applications in controlled release. Acc Chem Res 2007;40(9):846–53.13. Bonacchi S., Genovese D., Juris R. et al. Luminescent silica nanoparticles. extending the frontiers of brightness. Angew Chem Int Ed Engl 2011;50(18):4056–66.Bonacchi S., Genovese D., Juris R. et al. Luminescent silica nanoparticles. extending the frontiers of brightness. Angew Chem Int Ed Engl 2011;50(18):4056–66.14. Xie J., Huang J., Li X. et al. Iron oxide nanoparticle platform for biomedical applications. Curr Med Chem 2009;16(10):1278–94.Xie J., Huang J., Li X. et al. Iron oxide nanoparticle platform for biomedical applications. Curr Med Chem 2009;16(10):1278–94.15. Torchilin V. P. Multifunctional, stimulisensi tive nanoparticulate systems for drug delivery. Nat Rev Drug Discov 2014;13(11):813–27.Torchilin V. P. Multifunctional, stimulisensi tive nanoparticulate systems for drug delivery. Nat Rev Drug Discov 2014;13(11):813–27.16. Hurst J. Chapter 9 – Boron nitride nanotubes, silicon carbide nanotubes, and carbon nanotubes – a comparison of properties and applications. In: Nanotube Superfiber Materials. Elsevier, 2014. Pp. 267–287.Hurst J. Chapter 9 – Boron nitride nanotubes, silicon carbide nanotubes, and carbon nanotubes – a comparison of properties and applications. In: Nanotube Superfiber Materials. Elsevier, 2014. Pp. 267–287.17. Ciofani G., Del Turco S., Genchi G. G. et al. Transferrin-conjugated boron nitride nanotubes: Protein grafting, characterization, and interaction with human endothelial cells. Int J Pharm 2012;436(1–2):444–53.Ciofani G., Del Turco S., Genchi G. G. et al. Transferrin-conjugated boron nitride nanotubes: Protein grafting, characterization, and interaction with human endothelial cells. Int J Pharm 2012;436(1–2):444–53.18. Ferreira T. H., Marino A., Rocca A. et al. Folate-grafted boron nitride nanotubes: possible exploitation in cancer therapy. Int J Pharm 2015;481(1–2): 56–63.Ferreira T. H., Marino A., Rocca A. et al. Folate-grafted boron nitride nanotubes: possible exploitation in cancer therapy. Int J Pharm 2015;481(1–2): 56–63.19. Li X., Wen G., Zhang T. et al. Synthesis of continuous boron nitride nanofibers by electrospinning. Physics Procedia 2012;25:185–8.Li X., Wen G., Zhang T. et al. Synthesis of continuous boron nitride nanofibers by electrospinning. Physics Procedia 2012;25:185–8.20. Lin L. X., Zheng Y., Li Z.-H. et al. A simple method to synthesize polyhedral hexagonal boron nitride nanofibers. Solid State Sci 2007;9:1099–104.Lin L. X., Zheng Y., Li Z.-H. et al. A simple method to synthesize polyhedral hexagonal boron nitride nanofibers. Solid State Sci 2007;9:1099–104.21. Lacerda L., Raffa V., Prato M. et al. Cellpenetrating CNTs for delivery of therapeutics. Nano Today 2007;2:38–43.Lacerda L., Raffa V., Prato M. et al. Cellpenetrating CNTs for delivery of therapeutics. Nano Today 2007;2:38–43.22. Yamakov V., Park C., Kang J. H. et al. Piezoelectric molecular dynamics model for boron nitride nanotubes. Computat Mater Sci 2014;95:362–70.Yamakov V., Park C., Kang J. H. et al. Piezoelectric molecular dynamics model for boron nitride nanotubes. Computat Mater Sci 2014;95:362–70.23. Ciofani G., Danti S., Genchi G. G. et al. Boron nitride nanotubes: biocompatibility and potential spill-over in nanomedicine. Small 2013;9(9–10):1672–85.Ciofani G., Danti S., Genchi G. G. et al. Boron nitride nanotubes: biocompatibility and potential spill-over in nanomedicine. Small 2013;9(9–10):1672–85.24. Salvetti A., Rossi L., Iacopetti P. et al. In vivo biocompatibility of boron nitride nanotubes: effects on stem cell biology and tissue regeneration in planarians. Nanomedicine 2015;10(12):1911–22.Salvetti A., Rossi L., Iacopetti P. et al. In vivo biocompatibility of boron nitride nanotubes: effects on stem cell biology and tissue regeneration in planarians. Nanomedicine 2015;10(12):1911–22.25. Sukhorukova I. V., Zhitnyak I. Y., Kovalskii A. M. et al. Boron nitride nanoparticles with petal-like surface as anticancer drug delivery system. ACS Appl Mater Interfaces 2015;7(31):17217–25.Sukhorukova I. V., Zhitnyak I. Y., Kovalskii A. M. et al. Boron nitride nanoparticles with petal-like surface as anticancer drug delivery system. ACS Appl Mater Interfaces 2015;7(31):17217–25.26. Tang C., Bando Y., Sato T., Kurashima K. A novel precursor for synthesis of pure boron nitride nanotubes. Chem Commun 2002;12:1290–1.Tang C., Bando Y., Sato T., Kurashima K. A novel precursor for synthesis of pure boron nitride nanotubes. Chem Commun 2002;12:1290–1.27. Bannikov G. A., Guelstein V. I., Montesano R. et al. Cell shape and organization of cytoskeleton and surface fibronectin in non-tumorigenic rat liver cultures. J Cell Sci 1982;54:47–67.Bannikov G. A., Guelstein V. I., Montesano R. et al. Cell shape and organization of cytoskeleton and surface fibronectin in non-tumorigenic rat liver cultures. J Cell Sci 1982;54:47–67.28. Park S. W., Lomri N., Simeoni L. A. et al. Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the uic2 shift assay. Cytometry A 2003;53(2):67–78.Park S. W., Lomri N., Simeoni L. A. et al. Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the uic2 shift assay. Cytometry A 2003;53(2):67–78.29. Richert N., Akiyama S., Shen D. et al. Multiply drug-resistant human KB carcinoma cells have decreased amounts of a 75-kDa and a 72-kDa glycoprotein. Proc Natl Acad Sci USA 1985;82(8): 2330–3.Richert N., Akiyama S., Shen D. et al. Multiply drug-resistant human KB carcinoma cells have decreased amounts of a 75-kDa and a 72-kDa glycoprotein. Proc Natl Acad Sci USA 1985;82(8): 2330–3.30. Dreher M. R., Liu W., Michelich C. R. et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006;98:335–44.Dreher M. R., Liu W., Michelich C. R. et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006;98:335–44.31. Champion J. A., Katare Y. K., Mitragotri S. Particle shape: A new design parameter for micro- and nanoscale drug delivery carriers. J Control Release 2007;121(1–2):3–9.Champion J. A., Katare Y. K., Mitragotri S. Particle shape: A new design parameter for micro- and nanoscale drug delivery carriers. J Control Release 2007;121(1–2):3–9.